Latest Conference Articles

November 10th 2014, 10:05am

PER® New York Lung Cancer Symposium

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

November 10th 2014, 9:48am

PER® New York Lung Cancer Symposium

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

November 10th 2014, 8:18am

PER® New York Lung Cancer Symposium

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

November 10th 2014, 7:05am

PER® New York Lung Cancer Symposium

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

November 10th 2014, 7:02am

PER® New York Lung Cancer Symposium

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

November 8th 2014, 9:26am

PER® New York Lung Cancer Symposium

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

November 7th 2014, 3:05pm

PER® New York Lung Cancer Symposium

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

November 7th 2014, 11:56am

PER® Chemotherapy Foundation Symposium (CFS)

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

November 7th 2014, 9:24am

PER® Chemotherapy Foundation Symposium (CFS)

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

November 6th 2014, 12:53pm

PER® Chemotherapy Foundation Symposium (CFS)

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

November 6th 2014, 12:41pm

PER® Chemotherapy Foundation Symposium (CFS)

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.

November 6th 2014, 12:25pm

PER® Chemotherapy Foundation Symposium (CFS)

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

November 5th 2014, 2:06pm

PER® Chemotherapy Foundation Symposium (CFS)

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

November 5th 2014, 1:03pm

PER® Chemotherapy Foundation Symposium (CFS)

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

November 5th 2014, 12:52pm

PER® Chemotherapy Foundation Symposium (CFS)

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms

November 5th 2014, 12:28pm

PER® Chemotherapy Foundation Symposium (CFS)

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

November 5th 2014, 11:28am

PER® Chemotherapy Foundation Symposium (CFS)

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma

November 2nd 2014, 12:20pm

Annual Meeting of the American Thyroid Association

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

November 2nd 2014, 12:05pm

Annual Meeting of the American Thyroid Association

Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer.

November 2nd 2014, 10:05am

Annual Meeting of the American Thyroid Association

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.